Hong Kong stock market movement: HUTCHMED (00013) shares rose more than 4%, up 3.86% as of press time to HK$21.52, with a turnover of HK$148 million.
On the news front, on November 2, HUTCHMED announced that regulatory applications for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) have been accepted in Europe and Japan.
Following the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) in September 2026 for this combination therapy in the same indication, the acceptance of these regulatory applications in Europe and Japan marks further progress in advancing this innovative targeted combination therapy to benefit patients globally.
Notably, the positive results from the global Phase III SAFFRON study supported this New Drug Application. The results were presented at the Presidential Symposium session of the 2026 European Society for Medical Oncology (ESMO) Annual Meeting and simultaneously published in The New England Journal of Medicine.
Comments